Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Japanese Journal of Clinical Oncology

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKota KawabataFOFumiharu OhkaRSRyuta Saito

Discussion

Loading...

Member takes

Overview

Randomized trial assesses overall survival in patients with refractory PCNSL, suggesting potential benefits of tirabrutinib over traditional treatment.

Key Points

  • The aim is to evaluate the non-inferiority of tirabrutinib compared to whole-brain radiotherapy in improving overall survival for patients with refractory PCNSL.
  • Multicenter, randomized phase II/III trial with 94 patients enrolled over 4 years.
  • Assessment includes comparisons of overall survival and impacts on functional deterioration and cognitive impairment.
  • Trial registered in Japan Registry of Clinical Trials (jRCT1031250645).
  • Data on overall survival rates will show whether tirabrutinib is non-inferior to WBRT.
  • Tirabrutinib may reduce rates of functional deterioration and cognitive impairment compared to standard treatment.

Cite This Study

Kawabata et al. (2026) studied this question.

synapsesocial.com/papers/6a362e91db0793dc1a5363achttps://doi.org/10.1093/jjco/hyag090
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma2025
  2. 2IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma2026
  3. 3P17.14.B A RETROSPECTIVE STUDY OF THE BTK-INHIBITOR TIRABRUTINIB FOR THE TREATMENT OF RECURRENT/REFRACTORY PRIMARY CNS LYMPHOMA2025
  4. 4DDDR-36. Tirabrutinib Therapy for Refractory or Relapsed Primary Central Nervous System Lymphoma: A Retrospective Analysis of 13 Cases2025
  5. 5Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study2025